Hypertension treatment and risk of cardiovascular disease or mortality across risk equations: results from SPRINT
- Journal
- Journal of hypertension (Q1)
- Published
- 23 July 2026
- Study design
- Unclassified
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- Benjamin Grobman, Frances M Wang, Azuka Amaka Ngige, Shreyas Rajesh, Mingyu Zhang, Timothy B Plante, et al.
- PMID
- 42554269
- DOI
- 10.1097/HJH.0000000000004397
Why clinicians should know about it
- Picked for Internal Medicine (paper of the day, 6 August 2026): SPRINT analysis shows intensive treatment benefits in high‑risk groups
Abstract
The 2025 AHA/ACC blood pressure (BP) management guidelines recommend BP treatment for 10-year cardiovascular disease (CVD) ≥7.5% from the PREVENT equation, replacing the prior pooled cohort equations (PCE). We examined associations between risk in PCE and PREVENT and a composite of CVD or cardiovascular death in SPRINT. Among 1794 participants, 477 (26.6%) were at low risk in both, 119 (6.6%) were high-risk in PREVENT only, 89 (5.0%) were high-risk in PCE only, and 1109 (61.8%) were high-risk in both. Those at high risk in both equations receiving intensive treatment had a lower risk of the primary outcome [hazard ratio (HR): 0.46, 95% confidence interval (CI): 0.24, 0.89]. Intensive treatment did not affect the risk of any outcomes for those at high-risk in PREVENT only or PCE only due to low event rates. These findings confirm the neutrality of the change from PCE to PREVENT for BP treatment recommendations.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.